Ver­tex gam­bles $950M on biotech buy­out, hunt­ing a cure for di­a­betes

Ver­tex Phar­ma­ceu­ti­cals $VRTX is spend­ing close to a bil­lion dol­lars to take a care­ful­ly aimed shot at cur­ing Type 1 di­a­betes.

Doug Melton Har­vard

The big cap biotech is pay­ing $950 mil­lion in cash to bag Sem­ma Ther­a­peu­tics, a biotech com­pa­ny that sprung out of decades of work by Har­vard pro­fes­sor Doug Melton. Five years ago Melton pub­lished a land­mark study show­ing the po­ten­tial for us­ing stem cells to cre­ate in­sulin-pro­duc­ing pan­cre­at­ic be­ta cells that were in­sert­ed in bulk in­to mice and suc­cess­ful­ly pro­tect­ed from an im­mune re­sponse — a break­through in re­gen­er­a­tive med­i­cine. 

Sem­ma’s team has been do­ing the pre­clin­i­cal ground­work for the hu­man stud­ies to come. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA